Alamar Biosciences, Inc. (ALMR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$26.91-1.75%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ALMR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Recent Highlights • Generated $33.5 million of total revenue for the third quarter of 2026, an increase of 68% as compared to the corresponding period of 2025 • Selected by UK Biobank to profile 80,0…
Stated in 1 of 1 supplied quarters. Management reported: ““He helped build the foundation that is driving our growth today, managed multiple rounds of fundraising, and leaves the company well-positioned for its next phase.” “Alamar is well positioned to lead the next era of proteomics, and I have never been more confident in the company’s future.””
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Not enough signal yet.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Recent Highlights • Generated $33.5 million of total revenue for the third quarter of 2026, an increase of 68% as compared to the corresponding period of 2025 • Selected by UK Biobank to profile 80,0…”
“Our selection by UK Biobank and new collaboration with GSK show that leading institutions and drug developers are choosing NULISA to reach the low-abundance proteome at scale.”
Stated in 1 of 1 supplied quarters. Management reported: ““He helped build the foundation that is driving our growth today, managed multiple rounds of fundraising, and leaves the company well-positioned for its next phase.” “Alamar is well positioned to lead the next era of proteomics, and I have never been more confident in the company’s future.””
““Our selection by UK Biobank and new collaboration with GSK show that leading institutions and drug developers are choosing NULISA to reach the low-abundance proteome at scale.””
Cash, cash equivalents, short-term investments and restricted cash were $231.5 million as of September 30, 2026.
Stated in 1 of 1 supplied quarters. Management reported: ““He helped build the foundation that is driving our growth today, managed multiple rounds of fundraising, and leaves the company well-positioned for its next phase.” “Alamar is well positioned to lead the next era of proteomics, and I have never been more confident in the company’s future.””
“Cash, cash equivalents, short-term investments and restricted cash were $231.5 million as of September 30, 2026.”
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.